News

The Centre for Ocular Research and Education is demonstrating its latest discoveries for eye applications at the Association for Research in Vision and Ophthalmology’s annual meeting in New Orleans.

Clearside Biomedical plans to open enrollment for their Phase 2b clinical trial of CLS-AX this quarter. Topline results are expected by the Q3 of 2024.

The company said this week it plans to open the trial for enrollment this quarter and expects topline results by the third quarter of 2024.

Reducing treatment burden, finding something other than a shot a month is key.

During a presentation at the Vit-Buckle Society meeting in Las Vegas, Sally S. Ong, MD, highlighted a new study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical and postoperative characteristics that affect best-corrected VA outcomes.

Complement Therapeutics GmbH secured financing to continue the development and complete a Phase Ib clinical proof of concept of its lead product CTx001, an AAV gene therapy for the treatment of GA secondary to dry-AMD.

Dr Ong and colleagues undertook a retrospective study of patients who underwent primary repair of uncomplicated RRDs at the Wilmer Eye Institute to examine the baseline, surgical, and postoperative characteristics that affect best-corrected VA (BCVA) outcomes.

The programme includes thousands of poster and paper presentations by up-and-coming vision scientists and world leaders in their respective subspecialties.

Aviceda Therapeutics announced that the FDA has cleared the Investigational New Drug application for AVD-104, enabling the company to proceed with initiation of Phase 2 clinical trials.

New GA Won't Wait campaign partners Apellis Pharmaceuticals Inc. with actor Henry Winkler. The goal of this campaign is to raise awareness and educate older adults and their families about geographic atrophy (GA).

A large cohort study found no association between the first messenger RNA COVID-19 vaccinations and acute retinal vein occlusions.

The GA Won’t Wait campaign is designed to help older adults and their families understand and recognize the symptoms of this progressive and irreversible disease.

As technology advances, innovations increase physician capabilities.

Findings from a recent study suggest that AO retinal imaging has the potential to become a sensitive marker for MS.

Physician outlines the latest emerging technologies to treat the condition.

A large cohort study found that there is no association between the first mRNA COVID-19 vaccinations and acute RVO.

Vance Thompson, MD, joined David Hutton, Managing Editor, Ophthalmology Times®, to provide an overview of his presentation on pearls for cataract surgery at the Real World Ophthalmology meeting.

Vance Thompson, MD, sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss his presentation at the Real World Ophthalmology meeting on Pearls for cataract surgery.

Sally S. Ong, MD, shares the key takeaways from her presentation, Predictors of Poor Visual Outcome After Repair of Uncomplicated Rhegmatogenous Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting.

Sean D. Adrean MD, FAAO, discusses the key takeaways from his presentation, Purposeful Pneumatic Induced Resorption of Submacular Fluid in Macula-off Retinal Detachments, at the 11th Annual Vit-Buckle Society meeting, April 13 to 15, in Las Vegas, Nevada.

The technology could prove to be the foundation for establishing a new biomarker of ocular diseases.

Jennifer Lim, MD, FARVO joined David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation on keratoprosthesis combined with vitrectomy surgery given at this year's Vit-Buckle Society meeting.

Study results see brolucizumab as a viable treatment for patients with neovascular age-related macular degeneration (nAMD) refractory to other anti-VEGF drugs.

Jennifer Lim, MD, FARVO sat down with David Hutton, Managing Editor, Ophthalmology Times®, to discuss her presentation at this year's Vit-Buckle Society meeting on keratoprosthesis combined with vitrectomy surgery.

Kala Pharmaceuticals KPI-012 receives FDA Fast Track designation as treatment for PCED with potential to treat retinitis pigmentosa and Stargardt disease.

Daraius Shroff, MD, developed the Triple S toolkit for hAM grafting for use during vitreoretinal surgery, which he described at the 2023 Vit-Buckle Annual Society meeting.